COVID-19

In this article the authors report an analysis of postmortem COVID-19 cases that provides proof of viremia and presence of replication-competent SARS-CoV-2 in extrapulmonary organs of immunocompromised patients, including heart, kidney, liver, and spleen.

The objective of this study was to investigate the association of SSRIs with outcomes in patients with COVID-19 by analyzing electronic health records (EHRs).

The objective of this study was to assess risk of incident or repeat psychiatric illness, fatigue, or sleep problems following SARS-CoV-2 infection and to analyze changes according to demographic subgroups.

In this study the authors aimed to investigate transmission and viral load kinetics in vaccinated and unvaccinated individuals with mild delta variant infection in the community.

In this article the authors aimed to use the data repositories of Israel's largest health-care organisation to evaluate the effectiveness of a third dose of the BNT162b2 mRNA vaccine for preventing severe COVID-19 outcomes.

In this trial, done at 43 centres in France, the authors randomly assigned patients receiving invasive mechanical ventilation for up to 72 h with COVID-19 and associated moderate-to-severe ARDS to receive either IVIG or placebo.

Adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned to receive concomitant administration of either an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine.

In this study the authors did a multicentric, open-label, Bayesian randomised, adaptive, phase 2/3 clinical trial, nested within the CORIMUNO-19 cohort, to test a superiority hypothesis.

In this article the authors aimed to report the results of a substudy within a phase 3 UK trial, by evaluating the safety, immunogenicity, and efficacy of NVX-CoV2373 when co-administered with licensed seasonal influenza vaccines.

In this randomised, controlled, open-label, platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19.

In this trial, nonhospitalized patients with symptomatic COVID-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression received a single infusion of sotrovimab at a dose of 500 mg or placebo.

In this study the authors used data on confirmed infection and severe disease collected from an Israeli national database for the period of July 11 to 31, 2021, for all Israeli residents who had been fully vaccinated before June 2021.

Safe, effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed in children younger than 12 years of age. In this article the authors present results for 5-to-11-year-old children.

The objective of this double-blind randomised controlled trial was to compare propranolol and topiramate in terms of tolerability and efficacy in preventing chronic migraine over 24 weeks.

Our authors of the month conducted a randomised, placebo-controlled, observer-blinded, multinational study to assess the safety, efficacy and immunogenicity of the BNT162b2 vaccine.